Recursion Pharmaceuticals (RXRX) EPS (Weighted Average and Diluted) (2020 - 2026)
Recursion Pharmaceuticals (RXRX) reported EPS (Weighted Average and Diluted) of -$0.22 for Q1 2026, up 56.0% on a YoY basis from -$0.14 in Q1 2025, and down 29.41% quarter-over-quarter from -$0.17 in Q4 2025.
Recursion Pharmaceuticals (RXRX) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 7 years, with the latest figure at -$0.22 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 56.0% year-over-year to -$0.22; the trailing twelve-month figure through Mar 2026 stood at -$1.16 (up 35.91% YoY), and the FY2025 full-year result was -$1.44, up 14.79% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at -$0.22, down from -$0.17 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was -$0.17 in Q4 2025, with the low at -$0.57 in Q4 2024.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.37 across 5 years, with a median of -$0.38 in 2022.
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) jumped 75.19% — and 2023, when it slumped 40.0%.
- Recursion Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.3 in 2022, then plunged by 40.0% to -$0.42 in 2023, then tumbled by 35.71% to -$0.57 in 2024, then jumped by 70.18% to -$0.17 in 2025, then retreated by 29.41% to -$0.22 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.22 (Q1 2026), -$0.17 (Q4 2025), and -$0.36 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Recursion Pharmaceuticals | 1.71 Bn | 1.05 Bn | -6.02 Mn | -0.22 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.22 |
| Dec 31, 2025 | -0.17 |
| Sep 30, 2025 | -0.36 |
| Jun 30, 2025 | -0.41 |
| Mar 31, 2025 | -0.50 |
| Dec 31, 2024 | -0.57 |
| Sep 30, 2024 | -0.34 |
| Jun 30, 2024 | -0.40 |
| Mar 31, 2024 | -0.39 |
| Dec 31, 2023 | -0.42 |
| Sep 30, 2023 | -0.43 |
| Jun 30, 2023 | -0.38 |
| Mar 31, 2023 | -0.34 |
| Dec 31, 2022 | -0.30 |
| Sep 30, 2022 | -0.35 |
| Jun 30, 2022 | -0.38 |
| Mar 31, 2022 | -0.33 |
| Dec 31, 2021 | -0.39 |
| Sep 30, 2021 | -0.28 |
| Jun 30, 2021 | -0.31 |